迈科康生物 迈科康生物

CN

We focus on the R&D and production of innovative vaccines and new adjuvants.

about

mAXVAX

We focus on the R&D and production of innovative vaccines and new adjuvants.

Maxvax Biotechnology was founded by Dr. Dexiang Chen in 2016 in China's south-western city of Chengdu. We are a global biopharmaceutical enterprise dedicated to the research, development, production and commercialization of innovative vaccines and new adjuvants.
More

Technology

& production

We provide customers with high-quality, safe
and innovative products.

Technology Platform

Maxvax has pioneered three technological platforms: recombinant protein, adjuvants, and mRNA, aimed at treating infectious diseases, cancer, and allergies.

Learn more

Technology
Platform

+

Pipeline Introduction

Utilizing our technology platforms, we have developed a diverse pipeline of prophylactic and therapeutic vaccines to combat global health burdens.

Learn more

Pipeline
Introduction

+

Production Capability

We have constructed over 200,000 sq ft of state-of-the-art R&D and manufacturing facilities to support our pipeline, enabling us to handle product development all the way to industrial scale manufacturing, all in-house.

Learn more...

Production
Capability

+

news

center

Maxvax Newsletters

  • 252025.12

    Financing Progress | Maxvax Announces Completion of D+ Round Financing

    In December 2025, Maxvax announced the completion of a D+ round financing totaling several hundred million RMB. This round was jointly invested by Chengdu Sci-Tech Investment, Shenzhen Capital Group, Guosheng Capital, and Linchuang Blue Bay. The funds raised will be primarily used to support the launch and commercialization of the recombinant herpes zoster (shingles) vaccine, the Phase III clinical trials of the recombinant respiratory syncytial virus (RSV) vaccine, as well as the preclinical development and international cooperation of multiple innovative vaccine pipelines.

    more >

  • 132025.11

    Maxvax receives funding to advance RSV maternal vaccine candidate into clinical evaluation

    Maxvax Biotechnology LLC (USA) recently announced that it has received funds from the Gates Foundation to support the development of its recombinant respiratory syncytial virus (RSV) maternal vaccine candidate.

    more >

  • 312025.10

    Financing Progress | Maxvax Completes Series D Financing, Raising Over RMB 400M

    Maxvax announced on October 31, 2025 the successful completion of its Series D financing round, raising over RMB 400 million. This round was jointly invested by IDG Capital, Shenzhen Capital Group (SCGC), and Ruipu Pharma. The funds will primarily support the clinical trials and commercialization preparation of Maxvax’s recombinant shingles (herpes zoster) vaccine, the Phase III clinical trial of its recombinant respiratory syncytial virus (RSV) vaccine, and preclinical research for multiple innovative vaccine candidates and international collaborations.

    more >
See more

contact

mAXVAX

We are here if you have any questions and needs.

  • Contact Us

  • Opportunities

  • Branches